News about Market

DOMINA and SOLIDA: New Generation of Tablet Presses from IMA Active

DOMINA and SOLIDA: New Generation of Tablet Presses from IMA Active

Let's take a look at a new generation of tablet presses from IMA Active, DOMINA and SOLIDA, which are poised to change the meaning of production in the pharmaceutical industry.

Market | 15/11/2025 | By Dineshwori |  570

SCRI and Bristol Myers Squibb Expand Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research

SCRI and Bristol Myers Squibb Expand Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research

SCRI and Bristol Myers Squibb have expanded their collaboration to accelerate patient enrollment and extend access to advanced cancer clinical trials. By leveraging a data-driven strategy, the partnership aims to bring innovative research opportunities to a broader range of communities.

Market | 15/11/2025 | By Dineshwori |  207

CPHI & PMEC India 2025: Romaco to Launch Noack N 950E Blister Packaging Machine with India-made Format Parts

CPHI & PMEC India 2025: Romaco to Launch Noack N 950E Blister Packaging Machine with India-made Format Parts

German-based pharmaceutical machinery manufacturer Romaco is expanding its footprint in India with the localisation of format part production for its Noack 900 blister packaging machine series.

Market | 15/11/2025 | By Dineshwori |  250

Zydus Receives Final Approval from USFDA for Leuprolide Acetate Injection

Zydus Receives Final Approval from USFDA for Leuprolide Acetate Injection

Zydus has secured final USFDA approval for its Leuprolide Acetate injection, a multiple-dose formulation indicated for the palliative treatment of advanced prostate cancer.

Market | 15/11/2025 | By Dineshwori |  248

Transition Bio and Voyager Therapeutics Partner to Advance TDP-43 Small-Molecule Therapies for ALS and FTD

Transition Bio and Voyager Therapeutics Partner to Advance TDP-43 Small-Molecule Therapies for ALS and FTD

Under the terms of the partnership, Transition Bio is responsible for the discovery and optimisation of small molecules targeting TDP-43 until nomination of a development candidate, upon which Voyager will have an option to license the worldwide exclusive rights to develop and commercialise the programme.

Market | 15/11/2025 | By Dineshwori |  393

FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer

FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer

The US FDA has cleared the OncoMate MSI Dx Analysis System as a companion diagnostic to guide pembrolizumab-based combination therapy in advanced endometrial cancer. The PCR-based assay determines microsatellite instability (MSI) status in tumour tissue, with support from Merck, developer of pembrolizumab and lenvatinib.

Market | 15/11/2025 | By Dineshwori |  399

Pfizer Cuts Majority of Its BioNTech Stake in Strategic Realignment

Pfizer Cuts Majority of Its BioNTech Stake in Strategic Realignment

After the sale, Pfizer now holds around 1.66 million American Depositary Shares, valued at roughly USD 163 million as of late September 2025.

Market | 14/11/2025 | By Darshana |  320

Merck Poised to Acquire Cidara Therapeutics in Deal Valued Above USD 3.3 Billion

Merck Poised to Acquire Cidara Therapeutics in Deal Valued Above USD 3.3 Billion

Merck & Co. is reportedly closing in on the acquisition of Cidara Therapeutics, a biotechnology company focused on long-acting antibody treatments for influenza. The deal is expected to value Cidara above its USD 3.3 billion market capitalisation.

Market | 14/11/2025 | By Darshana |  172

Natural Capsules Posts Stable Q2, but US Tariffs Slow HPMC Expansion

Natural Capsules Posts Stable Q2, but US Tariffs Slow HPMC Expansion

Natural Capsules, one of India’s leading capsule manufacturers, has announced its financial results for the quarter and half year ended September 30, 2025, reporting steady demand but acknowledging multiple external and operational challenges that have impacted growth.

Market | 14/11/2025 | By Dineshwori |  399

Lupin Receives EIR from US FDA for its Aurangabad (CSN) Facility

Lupin Receives EIR from US FDA for its Aurangabad (CSN) Facility

Lupin has received an Establishment Inspection Report (EIR) from the US FDA for its Aurangabad (CSN) facility, marking the successful closure of a product-specific Pre-Approval Inspection conducted between September 1 and September 5, 2025.

Market | 14/11/2025 | By Dineshwori |  293

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members